The Differences in the Characteristics of Insulin-producing Cells Using Human Adipose-tissue Derived Mesenchymal Stem Cells from Subcutaneous and Visceral Tissues

Yuma Wada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yu Saito, Shinichiro Yamada & Mitsuo Shimada

The aim of this study was to investigate the characteristics of insulin producing cells (IPCs) differentiated from adipose-tissue derived stem cells (ADSCs) isolated from human subcutaneous and visceral adipose tissues and identify ADSCs suitable for differentiation into efficient and functional IPCs. Subcutaneous and visceral adipose tissues collected from four (4) patients who underwent digestive surgeries at The Tokushima University (000035546) were included in this study. The insulin secretion of the generated IPCs was investigated using surface markers by: fluorescence activated cell sorting (FACS) analysis; cytokine release; proliferation ability of ADSCs; in vitro (glucose-stimulated insulin secretion: (GSIS) test); in vivo (transplantation into streptozotocin-induced diabetic nude mice). The less fat-related inflammatory cytokines secretions were observed ($P < 0.05$), and the proliferation ability was higher in the subcutaneous ADSCs ($P < 0.05$). Insulin expression and GSIS were higher in the subcutaneous IPCs ($P < 0.01$ and $P < 0.05$, respectively). The hyperglycaemic state of all mice that received IPCs from subcutaneous fat tissue converted into normo-glycaemia in thirty (30) days post-transplantation (4/4, 100%). Transplanted IPCs were stained using anti-insulin and anti-human leukocyte antigen antibodies. The IPCs generated from the ADSCs freshly isolated from the human fat tissue had sufficient insulin secreting ability in vitro and in vivo.

Type 1 diabetes mellitus (T1DM) is a chronic auto-immune disorder characterized by the destruction of pancreatic β-cells due to insulitis and absolute insulin deficiency. Islet transplantation (ITx) is one of the treatment choices for freeing people with TIDM from a lifelong dependence on insulin injections and results in reducing the risk of hypoglycaemic events and other serious complications. However, it has been reported that ITx has a low insulin independent rate and there is difficulty in securing sufficient islets due to a severe donor shortage in some countries3,4. The possibility to resolve these urgent issues lies in the generation of insulin producing cells (IPCs) derived from mesenchymal stem cells (MSCs). Regarding the harvest location of MSCs, it has been reported that adipose-tissue derived stem cells (ADSCs) can be obtained by a less invasive procedure with lower ethical problems compared to other MSCs3–5. Thus, the focus of this study is on the ADSCs as a new cell source of MSCs6–8 and the establishment of a new 2-step protocol for the differentiation of IPCs from ADSCs with a short culture duration and functional efficiency9. Moreover, this 2-step protocol was modified into a xeno-antigen free and three-dimensional (3D) culture protocol10,11 which improved cell quality and function in vitro/in vivo and resulted in the normalization of diabetic nude mice blood glucose over 120 days12. In other words, this modified protocol is reaching the pre-clinical level of proof of a concept.

Accordingly, when considering the generation and clinical application of IPCs it is important to investigate optimal adipose tissue serving as the cell source. Therefore, this study currently focused on the procurement location of adipose tissue. The adipose tissue accumulates mainly in subcutaneous and visceral locations. It has already been reported that the microenvironments of adipose tissue such as immune-cells and various cytokines

Department of Surgery, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan. Correspondence and requests for materials should be addressed to T.I. (email: ikemoto.tetsuya@tokushima-u.ac.jp)
secreted from them differ, depending on the location of the adipose tissue\textsuperscript{13–16}. It is also reported that subcutaneous adipose cells are smaller in size and higher in differentiation and proliferation ability compared to visceral adipose cells\textsuperscript{13}. In addition, compared with visceral adipose tissue, there are three (3) times or more B cells in subcutaneous adipose tissue and these B cells suppress the activity of CD8\textsuperscript{+} T cells via IL-10 secretion and M1 macrophage which induce an inflammatory response\textsuperscript{16}. Therefore, there must be various functional and cell-fatal differences depending on the location of the adipose tissue due to the differences in the microenvironment.

In this study IPCs generated from ADSCs isolated from fresh human subcutaneous and visceral adipose tissues were characterized and the identification which ADSCs can achieve to differentiate into more efficient and functional IPCs was shown.

Results

The characteristic differences of isolated ADSCs. For the isolated ADSCs there were no differences in morphology between those from the subcutaneous and the visceral adipose tissues (Fig. 1A). On the one hand, in the FACS analysis, the results of CD31\textsuperscript{−}CD34\textsuperscript{−}CD45\textsuperscript{−}CD90\textsuperscript{+}CD105\textsuperscript{−}CD146\textsuperscript{−} were the same in both the subcutaneous and visceral ADSCs. In addition, compared with visceral adipose tissue, there are three (3) times or more B cells in subcutaneous adipose tissue and these B cells suppress the activity of CD8\textsuperscript{+} T cells via IL-10 secretion and M1 macrophage which induce an inflammatory response\textsuperscript{16}. Therefore, there must be various functional and cell-fatal differences depending on the location of the adipose tissue due to the differences in the microenvironment.

In this study IPCs generated from ADSCs isolated from fresh human subcutaneous and visceral adipose tissues were characterized and the identification which ADSCs can achieve to differentiate into more efficient and functional IPCs was shown.

The characteristic differences of isolated ADSCs. For the isolated ADSCs there were no differences in morphology between those from the subcutaneous and the visceral adipose tissues (Fig. 1A). On the one hand, in the FACS analysis, the results of CD31\textsuperscript{−}CD34\textsuperscript{−}CD45\textsuperscript{−}CD90\textsuperscript{+}CD105\textsuperscript{−}CD146\textsuperscript{−} were the same in both the subcutaneous and visceral ADSCs. In addition, compared with visceral adipose tissue, the results were CD31\textsuperscript{−}CD34\textsuperscript{−}CD45\textsuperscript{−}CD90\textsuperscript{+}CD105\textsuperscript{+}CD146\textsuperscript{−} for the commercially provided ADSCs, showing a difference between the two in only the CD105 component (Fig. 1B).

The cytokine release pattern was different between the ADSCs from the subcutaneous and visceral adipose tissues. Next, the cytokine release of each of the ADSCs was examined using the supernatants of the culture conditioned medium (Fig. 2A). There were differences in some cytokines between the subcutaneous and visceral ADSCs such as angiogenesis and inflammatory cytokines. These cytokines were: Angiogenesis; Chitinase 3-like 1 (CHI3LI); Interleukin-1\textsubscript{3} (IL-1\textsubscript{3}); Epidermal growth factor (EGF); Monocyte chemotactant protein-1 (MCP-1); Cystatin C (CST3); Interleukin-6 (IL-6); Interleukin-8 (IL-8); Pentraxin 3 (PTX3); Transforming growth factor-\beta (TGF-\beta); Plasminogen activator urokinase receptor (PLAUR); and Tumour necrosis factor-\alpha (TNF-\alpha) (Fig. 2B). These cytokines’ secretions were decreased in the supernatants of the ADSCs conditioned medium from the subcutaneous adipose tissue compared to that from the visceral adipose tissue (p < 0.05, Mann-Whitney U test, Fig. 2B). Moreover, we measured the days until 10 cm dish is confluent as the proliferation ability. It was higher in the subcutaneous ADSCs than that of the visceral ADSCs (3.3 days vs. 5.8 days, p = 0.04, Mann-Whitney U test, Fig. 2C). In terms of the growth rate, the subcutaneous ADSCs proliferated 1.75 times faster than the visceral ADSCs.
The cell qualities of the generated IPCs. There were no differences for the induced IPCs in morphology between those from the subcutaneous and visceral adipose tissues (Fig. 3A). In insulin and 4′,6-diamidino-2-phenylindole (DAPI) immunofluorescence, the cytoplasm of the generated IPCs was well stained on day twenty-one (21) (Fig. 3B). To estimate the number of generated IPCs the DAPI positive cells when counted showed an average count (n = 3) of 163. Thus it was calculated that there were 1.6 × 10⁴ cells in one IPC when an IPC was assumed to have a 300 μm diameter globular shape (Fig. 3C). As well, the number of cells was estimated by the quantity of the DNA of the ADSCs which was 88.4% preserved in the generated IPCs (from 3.2 × 10⁶ μg/mL/plate to 2.8 × 10⁶ μg/mL/plate, the average of three (3) independent plates, Fig. 3D). Thus it was calculated that, theoretically, 1.8 × 10⁴ cells existed in one IPC. Comparing generated IPCs from fat tissue procurement cites, there was a difference between the numbers of strongly insulin positive cells in the IPCs derived from the subcutaneous and from the visceral ADSCs (43.0 vs. 5.0/high power field, P = 0.01, Mann-Whitney U test, Fig. 3E,F).

In these generated IPCs the cytoplasm of many of the cells was well stained by C-peptide and PDX-1 antibodies on day twenty-one (21) (Fig. 3G,H).

The difference of generated IPCs for glucose stimulation. Next, the differences between the IPCs generated from the ADSCs isolated from the subcutaneous and the visceral adipose tissues were examined. A glucose stimulation test of the IPCs at day twenty-one (21) showed the insulin secretion capacity was higher in the subcutaneous IPCs than the visceral IPCs (subcutaneous IPC: 4.81, 3.84, 4.67, 1.86; visceral IPCs: 0.90, 1.86, 1.34, 2.02; median SI values of subcutaneous IPC vs visceral 3.8 vs. 1.5; P = 0.02, Mann-Whitney U test, Fig. 4).

In vivo functional assessment of the IPCs. From the results above, the in vivo function of IPCs derived from the ADSCs isolated from the subcutaneous fat tissue was investigated. The non-fasting blood glucose levels of the recipients (n = 4) are shown in Fig. 5A. In the sham group (n = 4), the blood glucose levels only increased and were never marked below 400 mg/dl throughout the experiment. In contrast, the blood glucose levels decreased gradually in the IPC group to below 200 mg/dl by day nine (9) after transplantation and stayed around 100 mg/dl up to thirty (30) days after transplantation (4/4, 100%).

Pathology of the transplanted IPCs. The transplanted IPCs were observed under the kidney capsule on day thirty (30) post-transplantation. RCP pieces were still observed in these clusters (Fig. 5B, upper). These clusters were well stained by anti-insulin and anti-human leukocyte antigen (HLA) class I (Fig. 5B, lower).
Discussion

ITx is potentially a curative treatment for people with TIDM. However, it currently requires multi-donors to secure enough islets to transplant into one recipient to achieve a successful outcome. Thus, the generation of IPCs has the possibility to resolve these urgent issues and ADSCs can be obtained by a less invasive procurement method with lower ethical problems. As the location to harvest ADSCs, this study focused on subcutaneous adipose tissue because of the safety and simplicity of procurement. It can be collected by local anaesthesia and can be often used from the disposal waste of plastic surgery (as stromal vascular fraction). Also, it is reported ADSCs derived from subcutaneous adipose tissue can be regenerated and used by dermatology and in plastic surgery\(^1\).\(^7\).\(^8\).\(^9\).\(^17\).\(^18\). However, abdominal surgeons generally use omentum (visceral adipose tissue) for the repair of gastrointestinal perforations\(^1\).\(^9\).\(^2\).\(^3\). The authors have also experienced that these perforative points were completely replaced with regenerated tissues by an omental patch, thus digestive surgeons often have the impression that omentum has superior self-renewal ability. Moreover, it has also been reported that omental ADSCs promote angiogenesis and cell proliferation\(^2\). Therefore, a major question focused on in this study was whether isolated ADSCs from subcutaneous adipose tissue are better than visceral fat tissue for generating superior functioning IPCs. At first, the surface markers of the ADSCs isolated from subcutaneous and visceral fat tissue were the same, even though CD105 was negative compared to the commercially available ADSCs. It is reported that CD105 is a co-receptor for transforming the growth factor beta (TGF\(\beta\)) receptor that antagonizes TGF\(\beta\) signalling and is also a marker for vascular endothelial cells\(^2\). Moreover, it is also reported that freshly isolated ADSC contains various cell types, and homogeneous CD105\(^+\) cells only remain after many passages on plastic dishes\(^3\).\(^4\).\(^5\). According to this report, CD105\(^-\) MSCs were more prone to differentiate and suppress the proliferation of CD4\(^+\) T cells compared to CD105\(^+\) MSCs. Moreover, the CD105\(^-\) cells showed superior differentiation potential in chondroid...
lesions compared to the CD105+ cells. Thus, the finding in this study may suggest that CD105− ADSCs could affect the differentiation potential toward IPCs, even though investigations should continue regarding the fate and cytokine secretory ability of CD105− ADSCs.

Regarding to cytokines, subcutaneous ADSCs were found to secret less fat-tissue related inflammatory cytokines and had better proliferation abilities. On the one hand, the IPCs from subcutaneous ADSCs showed better insulin secretory function and expressed more insulin levels in vitro, and converted the hyperglycaemic state of STZ-induced diabetic nude mice into normo-glycaemia in vivo. Originally, IPCs should be induced for each harvest location, and performed in-vivo functional test to compare the function. However, IPCs derived from the visceral adipose tissue still had a low SI level on day 21 and we considered that IPCs (Day 21) derived from them are not suitable for transplantation experiments because of immature condition (we previously examined that IPCs less than SI 3 is not resulted in normalizing blood glucose after transplantation, data not shown). So, we showed only transplantation results of IPCs derived from Sham and subcutaneous adipose tissue.

On the other hand, the visceral ADSCs were exposed to more inflammatory cytokines and the IPCs generated from them showed poor insulin secretion. Regarding characteristic differences, subcutaneous adipocytes secrete adiponectin and leptin which are regarded as low-density cholesterol, while visceral adipocytes secrete inflammatory cytokines such as: IL-6; TNF-α; MCP-1; PAI-1; and angiotensin II. It was reported that transforming growth factor-β (TGF-β) secreted from MSCs caused a decrease in cell viability and differentiation potential. In addition, multiple signalling cascades stimulated by interleukin-1β (IL-1β), interferon-γ (IFN-γ), and tumour necrosis factor-α (TNF-α) incited inducible nitric oxide synthase (iNOS) and resulted in apoptosis and inhibited functionality. This defect in cell activity is typically characteristic of impaired insulin biosynthesis and secretion, usually accompanied by oxidative and endoplasmic reticulum (ER) stress. In summary, the ADSCs derived from visceral adipose tissue secret more inflammatory cytokines and possible exposure to more oxidative and ER stress. The IPCs generated from them showed poor differentiation and insulin secretion.

Moreover, when considering the proper transplantation site, it is proposed that the intra-mesentery transplantation identified in a previous study is one reasonable and less-invasive transplantation site. As professional hepatobiliary-pancreatic and transplant surgeons, the authors routinely undergo high-risk laparoscopic surgeries. Thus it may be safe and easy for both recipients and surgeons to introduce intra-mesentery IPC transplantation as a Phase I/II study after considering the number of cells administered because the injection of a small amount into the mesentery is an easy technique when commercially available laparoscopic instruments are used.

Taken together, this study showed the possibility of an innovation to create IPCs from subcutaneous adipose tissue which was proved to have a more rapid differentiation rate and better functional efficiency compared to visceral adipose tissue. Moreover, that might be completely in agreement with the authors’ future research. That is: the intention to obtain 1.0 cm³ of adipose tissue from T1DM patients; to isolate and passage ADSCs from this tissue (approximately 1.0 × 10⁷ cells); to differentiate the cells into IPCs (approximately 88% cell numbers maintained) using the modified protocol identified in this study; and culture them without any genetic modifications. The generated IPCs would then be auto-transplanted into the patients’ mesentery laparoscopically. Within such concepts, these results may concretize a strategy for the clinical application of IPCs.
Materials and Methods

Research settings. Four (4) patients who had undergone digestive surgeries at The Tokushima University from 2018 to 2019 were included in this study. Both subcutaneous and visceral adipose tissues were collected and disposed as not necessary during the surgeries. This study was authorized in advance by the Institutional Review Board of the Tokushima University Hospital (the approved ID number: 3090) and the University Hospital Medical Information Network (the approved ID number: 000035546), was performed in accordance with relevant guidelines/regulations. All patients provided written informed consents.

Cell preparation. 0.1 gram of adipose tissue was harvested from each patient’s subcutaneous tissue and hepatic round ligament in the sterile environment during operation. ADSCs were obtained two (2) weeks later using a adipose stem cell isolation kit (Funakoshi Co, Tokyo, Japan) and passaged with ADSCs basal medium mixture of MesenPRO™ RS (Gibco, Carlsbad, CA) and GlutaMAX™-1 (Gibco). After three (3) passages, the ADSCs were counted and mixed with recombinant peptide micro-pieces (RCP μ-pieces, FUJIFILM, Tokyo, Japan), and injected into all of the wells in a Nunchlon Sphera 96U Bottom Plate (Thermo fisher scientific, Waltham, MA) as a 3D culture. The protocol for induction of IPCs was modified from the authors’ previous reported protocol9. Specifically, the contents of the differentiation cocktail were changed to recombinant human activin-A, hepatocyte growth factor and human albumin. The ADSCs were cultured using the Step-1 (from day 0 to day 7) medium containing: Dulbecco’s modified Eagle’s medium/F12 (Gibco); 1% recombinant human albumin (Wako, Osaka, Japan); exendin-4 (Sigma-Aldrich, St. Louis, MO); 1% N2 supplements (Gibco); 1% B27 supplements (Gibco); and 50 ng/mL recombinant human activin-A (PeproTech Inc., Rocky Hill, NJ). Step-2 (from day 8 to day 21) was prepared the same way as Step-1 medium with the addition of: 50 ng/mL recombinant human hepatocyte growth factor (PeproTech Inc.); valproic acid (Wako); and 10 mM nicotinamide (Sigma-Aldrich). The culture medium was changed and supernatant was collected every two (2) days. STEMPRO™ Human Adipose-Derived Stem Cells (Invitrogen, Grand Island, NY) was purchased and used for fluorescence activated cell sorting (FACS) analysis.

Figure 5. In vivo functional test. (A) Ninety-six (96) IPCs generated from the ADSCs and isolated from the subcutaneous adipose tissue were transplanted under the kidney capsule of streptozotocin-induced diabetic nude mice (n = 4, each mouse received IPCs from a different patient). In the sham group (n = 4), the blood glucose level remained at a high level. However, in the IPC-Tx group, the non-fasting blood glucose level decreased gradually after transplantation and remained normal. (B) Transplanted IPCs were observed under the kidney capsule on day thirty (30) post-transplantation (HE stains, upper left, yellow arrowheads). RCP pieces were still observed in these clusters (HE stains, upper left, white arrows). These clusters were well stained by anti-insulin antibody (lower left) and anti-human leukocyte antigen (HLA) class I (lower right). Scale bar; 30 µm.
**FACS analysis.** 2.0 × 10^6 ADSCs were washed twice with Phosphate Buffered Saline (PBS) (SANTA CRUZ Bio, Dallas, TX) and added to 100 μL of FACS buffer and 5 μL of each antibody: CD31 (Thermo Fisher scientific); CD34 (Thermo Fisher scientific); CD45 (BioLegend, San Diego, CA); CD90 (Thermo Fisher scientific); CD105 (Thermo Fisher scientific); and CD146 (BioLegend). After thirty (30) minutes in a dark room, the cells were analysed using FACSVerse and BD FACSuite software (BD Biosciences, San Paulo, Brazil).

**Glucose-stimulated insulin secretion (GSIS) test.** To determine the in vitro potency of the IPCs, the insulin secretory response to glucose was measured using a modified method previously described. Briefly, 10 IPCs were randomly transferred to a cell culture insert with: Krebs buffer (115 mM NaCl; 5.0 mM KCl; 2.3 mM CaCl₂; 1.0 mM MgCl₂; 1.2 mM KH₂PO₄; 25 mM NaHCO₃; pH 7.4); 25 mM HEPES (Gibco); and 0.1% BSA fraction V (Sigma-Aldrich) containing 2.8 mM glucose and incubated at 37 °C for one (1) hour as pre-incubation. Thereafter, the IPCs were suspended three (3) times for one (1) hour at 37 °C in Krebs buffer with the addition of various glucose concentrations (basal I: 2.8 mM; stimulation: 22 mM, respectively). The insulin level was measured using an Insulin Enzyme-Linked Immunosorbent Assay Kit (AKRIN-011T, Wako Shibayagi Corporation, Gunma, Japan).

**Immunofluorescence and confocal microscopy.** The IPCs in the culture medium were fixed with iP gel® (Nippon Genetics Corporation, Tokyo, Japan) and 10% formalin (Gibco), embedded in optical cutting temperature compound and frozen. Then 4-μm-thick sections were cut, rinsed in PBS and 5% BSA, and incubated with Universal Blocker Reagent for thirty (30) minutes in a humidified chamber at room temperature. Thereafter, sections were incubated with primary antibodies, anti-insulin (1:100 dilution; 4590, Cell Signaling Technology, Tokyo, Japan) overnight at 4 °C in a humidified chamber. After being washed with PBS and 4',6-diamidino-2-phenylindole (DAPI; Invitrogen Corp, Carlsbad, CA) the sections were applied to the slides and incubated at room temperature for two (2) hours in the dark. The cellular composition was determined by manu tally counting the stained cells using a fluorescent microscope (Keyence, Keyence Corp, Chicago, IL).

**Cell number estimation of IPCs by DNA quantity.** DNA quantity was measured using a DNA Quantity kit (Cosmo Bio, Tokyo, Japan) according to the manufacturer's protocol. Briefly, ADSCs and IPCs were washed with phosphate-buffered saline (PBS) and homogenized ultrasonically after a 0.5 ml buffer was added to each well. Then absorbance at 450 nm was measured using a plate reader (SpectraMax i3; Molecular Devices, Tokyo, Japan) at a correction wavelength of 540 nm.

**Cell count of IPCs (mathematically).** DAPI positive cells on 4 μm thickness were counted for using immunofluorescence images. Assuming that an IPC was a globular shape, that cell density was homogeneous and that the cutting plane was a perfect circle with the radius of z μm, the estimated IPC cell numbers can be found using this formula. A cell count on the cutting plane: estimated the IPC cell numbers = z²π × 4: 4/3π × (average IPC diameter)³.

**Dithizone staining.** The cultured cells were stained using a dithizone solution. The dithizone solution consisted of 50 mg dithizone (Wako) per 5 mL dimethyl sulfoxide (Wako). The IPCs were incubated in dithizone solution under 37 °C and 5% CO₂ conditions after being washed by PBS three (3) times. Stained samples were investigated using a multi-purpose microscope BZ-X710 (KEYENCE Engineering, Japan) and BZ-X analyser (KEYENCE Software, Japan).

**Cytokine assay.** A Human XL Cytokine Array Kit (R&D SYSTEMS., Minneapolis, MN) was used to measure each cytokine secretion of the ADSCs conditioned medium. The ADSCs were confluent and harvested in each conditioned medium. The procedure used was in accordance with the cytokine assay protocol. Briefly, each membrane was placed in a separate well and incubated with the array buffer for one (1) hour. Samples were prepared by diluting the desired quantity with the array buffer. After aspirating the array buffer and adding prepared samples, they were incubated overnight at 2–8 °C on a rocking platform shaker. Each membrane was washed and added to the diluted detection antibody cocktail then incubated for one (1) hour. After incubation, the prepared Chemi Reagent Mix was inserted onto each membrane. The membrane was exposed to X-ray film and analysed pixel density in each spot of the array.

**IPCs transplantation.** Eight (8) week-old male BALB/c nu-nu mice (Charles River Laboratories, Kanagawa, Japan) were used as the recipients (n = 4). The mice were allowed free access to water and standard laboratory food and were housed at a temperature of 22 ± 2 °C, relative humidity of 55 ± 5%, and a twelve (12) hour light: twelve (12) hour dark cycle with lights. The present study was conducted in compliance with the Division for Animal Research Resources, Graduate School of Biomedical Sciences, Tokushima University (approved number: T29-29). The experiments and procedures were approved by the Animal Care and Use Committee of the University of Tokushima and were performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals.

To induce a diabetic state in the mice, 200 mg/kg streptozotocin (STZ, Sigma-Aldrich) was administered intra-peritoneal as a single injection. The diabetic states were defined after two (2) consecutive measurements of blood glucose over 350 mg/dl or one (1) measurement over 400 mg/dl with a glucometer (Terumo Corporation, Tokyo, Japan). Then, ninety-six (96) IPCs were carefully hand-picked and transplanted under the kidney capsule of the streptozotocin-induced diabetic nude mice (n = 4, each mouse received IPCs from a different patient). The non-fasted glucose levels of all the mice were measured from the tail vein every one (1) or two (2) days after surgery.
**Immunohistochemical staining.** Generated cells and exirpted organs were prepared and stained by methods already reported. Briefly, generated IPCs were fixed using a cell fixing kit (Funakoshi), recipient mice were sacrificed and IPCs bearing kidneys were extirpated. 4μm thick paraffin embedded sections were incubated with primary antibodies against insulin (aa287–299, LS-B129, LSBio) at a dilution of 1:100 in phosphate-buffred saline (PBS), anti-HLA class I (ab70328; abcam) 1:100 in PBS, C-peptide (bs-0274R, Funakoshi) 1:100 in PBS and pancreatic and duodenal homeobox 1 (PDX-1, ab47308; abcam) 1:200 in PBS for 1 h at room temperature after deparaffinization and antigen retrieval. Slides were then incubated with biotinylated secondary antibody, followed by treatment with a streptavidin-biotin-horseradish peroxidase complex. Positive staining was visualized with diaminobenzidine and cell nuclei were counterstained with Mayer's haematoxylin.

**Statistical analysis.** The data analysis was performed with statistical software (JMP software, version 13; SAS Campus Drive, Cary, NC). Comparisons between the two (2) groups were performed by Mann-Whitney U test. The One-way ANOVA with Turkey-Kramer’s test was used to compare in vivo functional test. In the figures, the median values (75th and 25th percentiles) and median ± standard deviation (SD) are given, respectively. A value of p < 0.05 was considered to indicate statistical significance.

**Data Availability**

The datasets used and/or analyzed in this study are available from the corresponding author upon request.

**References**

1. Ryan, E. A. et al. Five-year follow-up after clinical islet transplantation. *Diabetes*. 54, 2060–9 (2005).
2. Pellegrini, S., Piemonti, L. & Sorli, V. Pluripotent stem cell replacement approaches to treat type 1 diabetes. *Curr Opin Pharmacol.* 43, 20–6 (2018).
3. Secco, M. et al. Multipotent stem cells from umbilical cord: cord is richer than blood! *Stem Cells*. 26, 146–50 (2008).
4. Zük, P. A. et al. Human adipose tissue is a source of multipotent stem cells. *Mol Biol Cell*. 13, 4279–95 (2002).
5. Dossena, M. et al. Human adipose-derived mesenchymal stem cells as a new model of spinal and bulbar muscular atrophy. *PLoS One*. 9, e112746 (2014).
6. Saito, Y. et al. Homing effect of adipose-derived stem cells to the injured liver: the shift of stromal cell-derived factor 1 expressions. *J Hepatobiliary Pancreat Sci*. 21, 873–80 (2014).
7. Saito, Y. et al. The protective effect of adipose-derived stem cells against liver injury by trophic molecules. *J Surg Res*. 180, 162–8 (2013).
8. Usunomiya, T. et al. Human adipose-derived stem cells: potential clinical applications in surgery. *Surg Today*. 41, 18–23 (2011).
9. Ikemoto, T. et al. A New 2-Step Acceleration Protocol Using a Histone Deacetylase Inhibitor to Generate Insulin-Producing Cells From Adipose-Derived Mesenchymal Stem Cells. *Pancreas*. 47, 477–481 (2018).
10. Nakamura, K., Iwazawa, R. & Yoshioka, Y. Introduction to a new cell transplantation platform by recombinant peptide petaloid pieces and its application to islet transplantation with mesenchymal stem cells. *Transpl Int*. 29, 1039–50 (2016).
11. Nakamura, K. CellSaic, A Cell Aggregate-Like Technology Using Recombinant Peptide Pieces for MSC Transplantation. *Curr Stem Cell Res Ther*. 14, 52–6 (2019).
12. Ikemoto, T. et al. *In vitro* and *in vivo* effects of insulin-producing cells generated by xen-o-antigen free 3D culture with RCP piece. *Sci Rep.* 9, 10759 (2019).
13. Leyvraz, C., Verduno, C. & Giusti, V. Localization of adipose tissue: clinical implications. *Rev Med Suisse*. 4, 844–7 (2008).
14. Petrus, P. et al. Transforming Growth Factor-β3 Regulates Adipocyte Number in Subcutaneous White Adipose Tissue. *Cell Rep.* 25, 551–60 (2018).
15. Li, H. et al. Fibroblast growth factor 21 increases insulin sensitivity through specific expansion of subcutaneous fat. *Nat Commun*. 9, 272 (2018).
16. Nishimura, S. et al. Adipose Natural Regulatory B Cells Negatively Control Adipose Tissue Inflammation. *Cell Metab*. 18, 759–66 (2013).
17. Chen, Y. W. et al. The effects of adipose-derived stem cell-differentiated adipocytes on skin burn wound healing in rats. *J Burn Care Res*. 38, 1–10 (2017).
18. Gaur, M., Dobke, M. & Lunyak, V. V. Mesenchymal stem cells from adipose tissue in clinical applications for dermatological indications and skin aging. *J Int Med Sci*. 18, E207 (2017).
19. Bonin, I. A. et al. Omentum patch substitute for facilitating endoscopic repair of GI perforations: an early laparoscopic pilot study with a foam matrix plug (with video). *Gastrointest Endosc*. 77, 123–30 (2013).
20. Poris, S. et al. Routine versus selective upper gastrointestinal contrast series after omental patch repair for gastric or duodenal perforation. *Surg Endosc*. 32, 400–4 (2018).
21. Ann, H. et al. Omental adipose tissue-derived stromal cells promote vascularization and growth of endometrial tumors. *Clin Cancer Res*. 18, 771–82 (2012).
22. Walker, D. G., Lue, L. F., Beach, T. G. & Tooyama, I. Microglial Phenotyping in Neurodegenerative Disease Brains: Identification of Reactive Microglia with an Antibody to Variant of CD105/Endoglin. *Cells*. 8, 766 (2019).
23. Sacchetti, B. et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. *Cell*. 131, 324–36 (2007).
24. Anderson, P., Carrillo-Gálvez, A. B., García-Pérez, A., Cobo, M. & Martín, F. CD105 (endoglin)-negative murine mesenchymal stromal cells define a new multipotent subpopulation with distinct differentiation and immunomodulatory capacities. *PLoS One*. 8, e76979 (2013).
25. Asai, S. et al. Tendon progenitor cells in injured tendons have strong chondrogenic potential: the CD105-negative subpopulation induces chondrogenic degeneration. *Stem Cells*. 32, 3266–77 (2014).
26. Rosen, E. D. & Spiegelman, B. M. Adipocytes as regulators of energy balance and glucose homeostasis. *Nature*. 444, 847–53 (2006).
27. Wu, Y. et al. Mesenchymal stem cells suppress fibroblast proliferation and reduce skin fibrosis through a TGF-β3-dependent activation. *Int J Low Extrem Wounds*. 14, 50–62 (2015).
28. Barrachina, L. et al. Priming Equine Bone Marrow-Derived Mesenchymal Stem Cells with Proinflammatory Cytokines: Implications in Immunomodulation-Immunogenicity Balance, Cell Viability, and Differentiation Potential. *Stem Cells Dev*. 26, 15–24 (2017).
29. Turkvæ, K. & Welsh, N. Aromatic mononitriles stimulate the resistance of insulin-producing beta-cells to oxidants and inflammatory cytokines. *Eur J Pharmacol*. 784, 69–80 (2016).
30. Faloon, P. W. et al. Identification of Small Molecule Inhibitors that Suppress Cytokine-Induced Apoptosis in Human Pancreatic Islet Cells. Probe Reports from the NIH Molecular Libraries Program (2011).
31. Clark, A. L. et al. Targeting Cellular Calcium Homeostasis to Prevent Cytokine-Mediated Beta Cell Death. *Sci Rep*. 7, 5611 (2017).
32. Sarr, O. et al. Subcutaneous and Visceral Adipose Tissue Secretions from Extremely Obese Men and Women both Acutely Suppress Muscle Insulin Signaling. *Int J Mol Sci.* 18, E959 (2017).
33. Balbaa, M., Abdulmalek, S. A. & Khalil, S. Oxidative stress and expression of insulin signaling proteins in the brain of diabetic rats: Role of Nigella sativa oil and antidiabetic drugs. *PLoS One.* 12, e0172429 (2017).
34. Hasnain, S. Z. et al. Glycemic control in diabetes is restored by therapeutic manipulation of cytokines that regulate beta cell stress. *Nat Med.* 20, 1417–26 (2014).
35. Yamashita, S. et al. Two cases of non-mucinous cystadenomas of the pancreas with pancreaticobiliary phenotype and ovarian-like stroma. *Surg Case Rep.* 23, 117 (2019).
36. Saito, Y. et al. A learning curve for laparoscopic cystadenoma resection: an effective training system and standardization of technique. *Transl Gastroenterol Hepatol.* 23, 45 (2018).
37. Yamada, S. et al. Effective stepwise training and procedure standardization for young surgeons to perform laparoscopic left hepatectomy. *Surg Endosc.* 31, 2623–2629 (2017).
38. Hannan, N. R. et al. Generation of multipotent foregut stem cells from human pluripotent stem cells. *Stem Cell Reports.* 1, 293–306 (2013).
39. Maehr, R. et al. Generation of pluripotent stem cells from patients with type 1 diabetes. *Proc Natl Acad Sci USA* 106, 15768–73 (2009).
40. Sakata, N. et al. Optimization of glucose level to determine the stimulation index of isolated rat islets. *Pancreas.* 36, 417–23 (2008).

**Acknowledgements**

We thank Gail Perry PhD, MBA, BA, BE, BN from Ajet English Service for editing a draft of this manuscript. We also thank Drs. Yusuke Arakawa and Kazunori Tokuda for assistance with ELISA and pathological investigations and thank B.S. Yumi Horikawa for technical support.

**Author Contributions**

Y.W. and T.I. designed the study; Y.W., T.I., Y.M., S.I., Y.S., and M.S. performed analysis and interpretation of the data; Y.W. and T.I. wrote the paper; T.I. and M.S. checked all the experiments and edited the manuscript; all authors reviewed this manuscript.

**Additional Information**

**Competing Interests:** Dr. Ikemoto and Dr. Shimada’s work were funded by the Regenerative Medicine Cooperative of Fujifilm Corporation and Tokushima University. Dr. Ikemoto, Dr. Yamada, Dr. Saito, Dr. Morine and Dr. Imura’s work were also funded partly by grants-in-aid for Scientific Research from the Ministry of Education, Science and Culture of Japan (Grant Nos 16K10429 and 19K09045). Dr. Ikemoto and Dr. Shimada’s works were also funded partly by a grant from the Japan IDDM network. Dr. Wada declares no potential conflict of interest.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019